A phase 2 randomized clinical trial finds no overall survival difference for an everolimus/letrozole backbone with ribociclib in recurrent endometrial cancer, but it reports subgroup-specific signals. Potential benefits appear in patients with prior endocrine therapy or CTNNB1 mutations. The result matters because recurrent endometrial cancer remains heterogeneous, and prior endocrine exposure and CTNNB1 status can reflect distinct underlying biology. Even with a negative overall endpoint, subgroup findings can guide future enrichment strategies and biomarker-led phase 3 designs. Companies and clinicians will now assess whether these subgroup markers are reproducible and whether the regimen’s safety profile remains acceptable in the enriched populations.
Get the Daily Brief